For instance, serial ctDNA monitoring for anti-EGFR resistance mutations identified colorectal cancer patients who benefited from rechallenge with anti-EGFR therapy, with one-third of patients lacking detectable circulating resistance variants showing further responses upon rechallenge [129]. The gene discussed is EGFR; the disease is colorectal cancer.